Actavis Only Requires Scrutiny Of Cash Deals, Judge Says

Law360, New York (January 24, 2014, 10:24 PM EST) -- A New Jersey federal judge on Friday again dismissed a proposed antitrust class action against GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. over their agreement postponing the production of a generic epilepsy drug, saying a Supreme Court decision changing the way to evaluate such deals' legality led him to the same conclusion.

U.S. District Judge William H. Walls rejected a motion by the direct purchasers of Lamictal to reconsider his original dismissal of their suit, saying the high court's landmark decision in Federal Trade Commission v....
To view the full article, register now.